Premium
Octreotide administration, under particular temporal conditions, enhances the responses of growth hormone to growth hormone‐releasing hormone in normal subjects
Author(s) -
Valcavl Roberto,
Zinl Michele
Publication year - 1994
Publication title -
clinical endocrinology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.055
H-Index - 147
eISSN - 1365-2265
pISSN - 0300-0664
DOI - 10.1111/j.1365-2265.1994.tb03935.x
Subject(s) - octreotide , somatostatin , medicine , endocrinology , growth hormone–releasing hormone , placebo , bolus (digestion) , hormone , peptide hormone , basal (medicine) , growth hormone , insulin , alternative medicine , pathology
Summary OBJECTIVE Somatostatin not only inhibits basal and GHRH‐stimulated GH secretion but might also enhance pituitary GH responsivity to GHRH under different temporal conditions. We investigated whether octreotide, a long‐acting somatostatin analogue, has any positive actions on GHRH‐induced GH release in normal human subjects. DESIGN The study consisted of three protocols. At 0800 hours, after fasting overnight, all subjects received 1 μg/kg GHRH l.v. bolus at 0 minutes. In each protocol, either octreotide (200 μg s.c.) or placebo were given respectively 8, 12, or 16 hours prior to GHRH challenge. SUBJECTS Three groups of eight normal volunteers (four female and four male in each group), aged 18–35 years, were randomly assigned to each protocol. MEASUREMENTS Growth hormone was measured by IRMA. Samples for GH assay were taken at −30 and 0 minutes and then at 15‐minute intervals up to 120 minutes. RESULTS When placebo or octreotide were administered 8 hours before GHRH, peak GH levels were respectively (mean ± SE, mU/l) 56·2 ± 16·6 and 60·8 ± 11·4 (NS). Also, when placebo or the somatostatin analogue were administered 16 hours prior to GHRH, peak GH levels were comparable (61·0 ± 7·4 vs 58·8 ± 7·4, NS). However, in the group receiving placebo or octreotide 12 hours prior to GHRH, the GH responses to GHRH were clearly enhanced by octreotide administration (peak GH levels, mU/l, 55·6 ± 21·6 vs 104·0 ± 17·4, P < 0·02). This enhancement of GH responses was observed in all subjects. CONCLUSIONS Octreotide administration did not affect GH responses to GHRH when given either 8 or 16 hours prior to GHRH. However, octreotide enhanced GHRH‐induced GH release when administered 12 hours prior to GHRH. It thus appears that, under particular temporal conditions, octreotide may act positively on GH secretion in man.